Triple

T5932639
Position Surface form Disambiguated ID Type / Status
Subject ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals E131972 entity
Predicate title P38 FINISHED
Object ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals E131972 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals | Statement: [ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals, title, ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
Context triple: [ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals, title, ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals]
  • A. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals chosen
    ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
  • B. Certificates of Suitability to the monographs of the European Pharmacopoeia
    Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
  • C. Molecular Cancer Therapeutics
    Molecular Cancer Therapeutics is a peer-reviewed scientific journal focusing on the discovery, development, and clinical evaluation of novel cancer therapeutics.
  • D. IARC Monographs on the Identification of Carcinogenic Hazards to Humans
    The IARC Monographs on the Identification of Carcinogenic Hazards to Humans are authoritative scientific evaluations that classify agents, mixtures, and exposures according to their potential to cause cancer in humans.
  • E. Centre for Cancer Biomarkers
    The Centre for Cancer Biomarkers is a research center focused on discovering, validating, and applying biomarkers to improve the diagnosis, prognosis, and treatment of cancer.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c0085b75e88190a632f9691f9da48b completed March 22, 2026, 3:18 p.m.
NER Named-entity recognition batch_69c0389df18c81909027a9db7596f0c1 completed March 22, 2026, 6:44 p.m.
NED1 Entity disambiguation (via context triple) batch_69c0c064d2a4819096085668182cfde1 completed March 23, 2026, 4:24 a.m.
Created at: March 22, 2026, 4 p.m.